Prodotti competitors / Area Oncology 16 febbraio 2024 Capivasertib (Truqap): delays in Phase 1b/3 CAPItello-290 trial evaluating capivasertib + CDK4/6i + fulvestrant in HR+/HER2- metastatic breast cancer
Prodotti competitors / Area Onco-Ema 7 novembre 2022 Trilaciclib (by G1 Therapeutics) has been granted Fast Track designation by FDA for the treatment of locally advanced or metastatic triple negative breast cancer (TNBC)
